In an interim analysis of a phase 1/2 trial in patients with glioblastoma, a genetically-engineered autologous stem cell transplant was well tolerated, with stable engraftment and evidence for immune reprogramming.
#cancerresearch
https://t.co/HkIYr8HIpH
95% of papers reporting antibody-based analysis of p16-INK4a used antibodies for an unrelated protein, p16-ARC.
Despite using the wrong antibody, authors reported the expected results:
> Genetic perturbations of p16-INK4a altered reported p16-ARC levels.
1/
I still remember reading about it in Siddhartha Mukherjee’s book when I was in med school. In a year, it will be 10 years into my cancer research career (started in med school + I just finished my PhD)
In 1948, Sidney Farber and colleagues published his work in @NEJM that helped open the door to modern chemotherapy.
Seeing that history from the same institution — especially after a remarkable #ASCO26 with major plenary contributions and @NEJM papers from @DanaFarber — is humbling.
A powerful reminder that progress in oncology is built across generations: by patients, scientists, clinicians, and teams who keep asking what might be possible.
I feel the problem would be picking which chromosome to eliminate (or add in case of deletions?) 🙃 (picture from the ichorCNA paper, but often there are even more alterations)
@exosome yes - aneuploidy is an under-appreciated driver of cancer, aging, and other significant conditions. we showed that in cancer, if you eliminate specific aneuploid chromosomes, you block malignant growth.
If you're a naturally anxious person, I recommend pursuing a high stress career path where at least you'll be compensated for anxiety you're going to have anyways.